摘要
目的探讨畲药地稔组方治疗急性缺血性脑卒中(acute ischemic stroke,AIS)的疗效,及对卒中后炎症因子、神经功能恢复及90 d生活独立能力的影响。方法选取2020年1月至2022年1月符合纳入标准的AIS患者193例,随机分为2组,对照组采用常规治疗;观察组在常规治疗基础上加用畲药地稔组方。两组患者治疗后第14天检测TNF-α、IL-1β、IL-6的浓度、NIHSS评分及90 dmRS评分,评估畲药地稔组方治疗的有效性;比较两组患者早期神经功能恶化、症状性颅内出血及90 d死亡率,明确畲药地稔组方的安全性。结果两组患者治疗14 d后,观察组TNF-α、IL-1β、IL-6水平低于对照组,观察组NIHSS评分低于对照组[(6.07±3.38)分VS.(7.19±3.53)分],观察组患者90 d获得生活独立能力的比例(mRs评分≤2分)明显高于对照组(52.6%VS.36.7%,P<0.05)。安全性方面,两组患者在早期神经功能恶化(9.5%VS.11.2%)、症状性颅内出血(5.3%VS.6.1%)及90 d死亡率(1.0%VS.2.0%),差异无统计学意义(P>0.05)。结论畲药地稔组方在AIS后72 h内给药,有助于降低炎症因子的释放,提高AIS患者90 d生活独立能力和促进神经功能恢复,从而改善卒中预后,降低致残率。
Objective To investigate the effect of She Medicine-Melastoma Dodecandrum Lour Formula on inflammatory factors,neurological function recovery and life independence on the 90th day after acute ischemic stroke(AIS).Methods Patients with AIS who met the inclusion criteria and were hospitalized in the Department of Neurology of Lishui Traditional Chinese Medicine Hospital between January 2020 and January 2022 were selected and randomly divided into two groups,with 193 patients finally included.Continuous 14 days of conventional treatment(the control group)or conventional treatment plus She Medicine-Melastoma Dodecandrum Lour Formula(the treatment group).The concentrations of TNF-α,IL-1βand IL-6,National Institutes of Health Stroke Scale(NIHSS)scores and 90-day modified Rakin Scale(mRS)scores were measured on day 14 after treatment in both groups to assess the effectiveness of She Medicine-Melastoma Dodecandrum Lour Formula treatment.Early neurological deterioration,symptomatic intracranial hemorrhage and 90-day mortality were compared between the two groups to clarify the safety of She Medicine-Melastoma Dodecandrum Lour Formula.Results After 14 days of treatment,the decrease of TNF-α,IL-1βand IL-6 in the treatment group was greater than that in the control group.The NIHSS score of the treatment group was significantly lower than that of the control group at 14 days[(6.07±3.38)points VS.(7.19±3.53)points].On the 90th day,the proportion of patients in the treatment group to obtain independent living ability(mRs score≤2 points)was significantly higher than that in the control group(52.6%VS.36.7%,P<0.05),and there was statistical difference in the efficacy between the two groups.In terms of safety,there was no significant difference in early neurological deterioration(9.5%VS.11.2%),symptomatic intracranial hemorrhage(5.3%VS.6.1%)and 90-day mortality(1%VS.2%)between the two groups(P>0.05).Conclusion The medication within 72 h after AIS in the She Medicine-Melastoma Dodecandrum Lour Formula group was helpful to re
出处
《浙江临床医学》
2024年第1期45-46,50,共3页
Zhejiang Clinical Medical Journal
基金
浙江省自然科学基金项目(LBY22H280001)
丽水市公益性重大科研项目(2021ZDYF16)
浙江省中医药科技计划科研项目(2024ZL869)
丽水市本级公益性研究项目(2020SJZC077)
宁波市卫生健康青年技术骨干培养项目(甬卫发[2024]87号)。
关键词
畲药地稔
急性缺血性脑卒中
神经功能恢复
She Medicine-Melastoma Dodecandrum Lour
Acute ischemic stroke
Neurological recovery
